Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 4,225 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Westminster, California • Kansas City, Kansas • Ann Arbor, Michigan + 6 more

Conditions: Myocardial Ischemia
Interventions: Not listed
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 21 Years to 81 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 16 more

Conditions: Lateral Epicondylitis
Interventions: rhPDGF-BB Injection, Placebo; Drug
Lead sponsor: BioMimetic Therapeutics; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 3 more

Conditions: Atopic Dermatitis
Interventions: Placebo, AK120; Drug
Lead sponsor: Akesobio Australia Pty Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 16
States / cities: Little Rock, Arkansas • Canoga Park, California • San Diego, California + 11 more

Conditions: Opioid Use
Interventions: Bupivacaine, Exparel 266 milligram Per 20 ML Injection, Saline; Drug
Lead sponsor: Santa Barbara Cottage Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions: Growth hormone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections, Lipodystrophy
Interventions: Placebo, Serostim® 4 mg, Serostim® 2 mg; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 22 more

Conditions: CBD, Healthy
Interventions: [11C]PBR28, Low-dose lipopolysaccharide, Intradermal Capsaicin; Radiation · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Barth Syndrome
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 5 Years to 55 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Needham, Massachusetts

Conditions: Psoriasis
Interventions: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg; Drug
Lead sponsor: Centocor Research & Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 28
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2944876, Exenatide extended-release, Placebo, Metformin; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 31
States / cities: Concord, California • Fresno, California • Los Angeles, California + 27 more

Conditions: Bilateral Nasolabial Fold Wrinkles
Interventions: Autologous Human Fibroblast (azficel-T), Placebo; Biological
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 7
States / cities: Birmingham, Alabama • Newport Beach, California • Coral Gables, Florida + 4 more

Conditions: Acute Spinal Cord Injury
Interventions: SUN13837 injection, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 40
States / cities: Tucson, Arizona • Downey, California • Los Angeles, California + 32 more

Conditions: SARS-CoV 2
Interventions: Tocilizumab, Placebos; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 3
States / cities: Boston, Massachusetts • Newton, Massachusetts

Conditions: Hidradenitis Suppurativa
Interventions: Lutikizumab, Placebo; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more

Conditions: Muscle Atrophy, ACL Reconstruction, Trauma, Osteoarthritis
Interventions: Testosterone, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
Interventions: IMG-007, Placebo; Drug
Lead sponsor: Inmagene LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 16
States / cities: Lancaster, California • Los Angeles, California • Ocala, Florida + 13 more

Conditions: Myocardial Infarction
Interventions: Tocilizumab, Placebo; Drug
Lead sponsor: Keesler Air Force Base Medical Center; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Keesler Air Force Base, Mississippi

Conditions: Obesity
Interventions: leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training; Drug · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy
Interventions: placebo acyline, placebo gel, Testosterone 1% gel 1.25 g, Testosterone 1% gel 2.5 g, Testosterone 1% gel 5.0 g, testosterone 1% gel 10 g, testosterone 1% gel 15 g, Acyline; Other · Drug
Lead sponsor: University of Washington; Other
Eligibility: 25 Years to 55 Years · Male only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
Interventions: Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 295 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Cypress, California • Glendale, California • Denver, Colorado + 4 more

Conditions: Chronic Spontaneous Urticaria
Interventions: QGE031, Omalizumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more

Conditions: Klinefelter Syndrome
Interventions: Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution, Placebo injectable saline; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 31 Days to 90 Days · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Atopic Dermatitis
Interventions: Tezepelumab, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 16
States / cities: Fountain Valley, California • Santa Monica, California • Alpharetta, Georgia + 12 more

Search by objective public record fields.

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)

Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

Laparoscopic Assisted Plane Block (LAPB) Trial

Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease

Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients

CBD-Microglia PET Study

Clinical Trial in Patients With Barth Syndrome- 4TAZPower

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles

Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)

Efficacy of Tocilizumab on Patients With COVID-19

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Testosterone Administration and ACL Reconstruction in Men

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Short-Term Application of Tocilizumab Following Myocardial Infarction

Prevention of Obesity in Women Via Estradiol Regulation

PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis